TripSit home
Contraindications Seizure disorder, current or prior diagnosis of bulimia or anorexia nervosa, abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and anti-epileptic drugs, and MAOIs
Warning Bupropion lowers the seizure threshold in a dose-dependent manner. Seizure risk increases significantly at total daily doses above 450 mg, with immediate-release formulations, rapid dose escalation, or when tablets are crushed or altered. Risk is further increased when combined with other substances that lower the seizure threshold, including CNS stimulants, alcohol (especially during withdrawal or binge use), theophylline, systemic corticosteroids, and certain antidepressants.
Chemical Name

Bupropion

Aliases

wellbutrin, zyban, amfebutamone

Categories

Stimulant

Summary

A frequently prescribed atypical antidepressant. Occasionally prescribed as an aid to smoking cessation. May lower seizure threshold in predisposed individuals. Poorly understood mechanism of action, probably an NDRI. Avoid combination with other drugs.

Adverse-effects

Agitation, dry mouth, insomnia, headache/migraine, nausea/vomiting, constipation, tremor, dizziness, excessive sweating, blurred vision, tachycardia, confusion, rash, hostility, cardiac arrhythmia, and auditory disturbance

Chemistry

IUPAC: (±)-2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one | Formula: C13H18ClNO | Molecular Mass: 239.74 g/mol

Contraindications

Seizure disorder, current or prior diagnosis of bulimia or anorexia nervosa, abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and anti-epileptic drugs, and MAOIs

Legal

Australia: Prescription Only (S4) | Canada: ℞-only | United Kingdom: POM | United States: ℞-only

Overdose-symptoms

Seizure, hallucinations, loss of consciousness, sinus tachycardia, ECG changes, bradycardia, cardiac failure, cardiac arrest, and death

Pharmacokinetics

Protein Binding: 84% (bupropion), 77% [hydroxybupropion (active metabolite)], 42% [threohydrobupropion (active metabolite)] | Metabolism: hepatic, primarily CYP2B6-mediated hydroxylation; both bupropion and hydroxybupropion (active metabolite) are CYP2D6 inhibitors | Excretion: renal (87%; 0.5% unchanged) and faecal (10%)

Pharmacology

NDRI (Norepinephrine-Dopamine Reuptake Inhibitor); NDRA (Norepinephrine-Dopamine Releasing Agent); α3β2, α3β4, α4β2, and α7 nACh receptor antagonist

Dosages

Light

Common

Strong

Heavy

Oral

150mg/day

150-300mg/day

300-450mg/day

450mg+/day

Durations

Onset

After Effects

Oral

15m to 1h 30m

1 to 6

Metabolites

Parent

Sources

Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. http://www.ncbi.nlm.nih.gov/pubmed/27518170dosing information for Bupropion https://www.mayoclinic.org/drugs-supplements/bupropion-oral-route/description/drg-20062478